Table 4.
Details of patients who achieved RECIST responses and clinical benefit at 4 or 6 months
| RECIST responders | CBR at 4 months | CBR at 6 months | |
|---|---|---|---|
| Total number of patients | 9 | 16 | 12 |
| Primary Site (no.) | |||
| Oesophagus | 6 | 11 | 8 |
| Stomach | 2 | 2 | 2 |
| Pancreas | 0 | 2 | 1 |
| Unknown | 1 | 1 | 1 |
| Previous lines chemotherapy (no.) | |||
| 1 | 3 | 4 | 4 |
| 2 | 6 | 12 | 8 |
| Chemotherapy containing regimen | |||
| Yes | 6 | 7 | 7 |
| No | 3 | 9 | 5 |
| Chemotherapy regimen used | |||
| Carboplatin/Paclitaxel | 1 | 2 | 2 |
| Docetaxel | 5 | 5 | 5 |
| Best RECIST Response | |||
| Stable disease | 0 | 7 | 3 |
| Partial response | 9 | 9 | 9 |
| PFS (weeks) | |||
| Median (95% CI) | 26.4 (21.0-31.9) | 26.4 (23.4-29.5) | 26.4 (23.3-29.6) |
| OS (weeks) | |||
| Median (95% CI) | 51.0 (16.8-85.2) | 54.4 (44.6-64.2) | 50.6 (36.3-64.9) |